Latest Videos Archives

Renorrhaphy Techniques During Partial Nephrectomy: Technical Points and Functional Outcomes

Posted by Pierluigi Bove, MD | Jul 2020

Pierluigi Bove, MD, Assistant Professor in Urology at the Tor Vergata University of Rome and Clinical Consultant at the University Polyclinic of Tor Vergata (Rome), argues that focusing on three goals— achieving parenchymal hemostasis at the end of the resection phase, ensuring closure of the collecting system, and avoiding indirect trauma—can help physicians decide which suturing technique to utilize. He explains the necessity of suturing experience, important aspects of the patient’s lesion and vascular anatomy to consider when decision-making, and how to utilize proper resection techniques in renorrhaphy.

Genetic Testing and Next Generation DNA Sequencing in Prostate Cancer

Posted by Alan H. Bryce, MD | Jul 2020

Alan H. Bryce, MD, Associate Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, gives an update on how and why to use germline and somatic testing in prostate cancer. He discusses updated National Comprehensive Cancer Network and Society of Urologic Oncology guidelines on who should receive germline and somatic testing, and notes that approved somatic therapies, including PARP inhibitors for BRCA1 and 2 and immunotherapy for microsatellite instability-high tumors, are only available to patients who have tested positive for the relevant mutations, underscoring the importance of widespread testing. Dr. Bryce also emphasizes the importance of germline testing for the patient’s family members, since the knowledge that they carry a hereditary cancer risk gene may allow them to receive early, life-saving cancer diagnoses. The presentation concludes with a Q&A session with E. David Crawford, MD, Professor of Urology at the University of California, San Diego, during which Drs. Crawford and Bryce discuss the limitations of taking a family history and how reimbursement works for multiple genetic tests.

Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19

Posted by Richard G. Harris, MD | Jul 2020

Richard Harris, MD, President of LUGPA and UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology. They discuss the challenges of managing prostate cancer patients during COVID-19, including the ways the pandemic has changed the manner and frequency of how they bring in patients in for treatment, particularly for therapies like androgen deprivation. Both Dr. Saltzstein and Dr. Langford emphasize the precautions they are taking at their practices to address the risks of COVID-19, and acknowledge how challenging this patient population can be given their need for frequent visits. They highlight the limitations of telehealth, as well as the risks of not bringing patients in often enough to receive the therapies that they need, even though lengthening the time between visits has been the answer a lot of doctors have found to reduce the risk of COVID-19 exposure.

Hiring Nonclinical Staff

Posted by Neil H. Baum, MD | Jul 2020

Neil H. Baum, MD, Clinical Professor of Urology at Tulane Medical School, discusses the business of medicine and some important numbers that urologists need to know. Highlighting the need for doctors to improve their business skills in order to survive in today’s market, Dr. Baum goes over five important metrics that will help doctors truly understand the value of the service they are providing. These numbers include charges and receipts, accounts receivable, charge lag, denials, and new patient percentages. He talks about what these numbers look like in a perfect world versus reality and what doctors can do about them. Dr. Baum emphasizes that doctors need only spend five minutes every month monitoring these metrics in order to become more involved in the business of their practice.

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Posted by Veda N. Giri, MD | Jul 2020

Veda N. Giri, MD, Director of Cancer Risk Assessment and Clinical Cancer Genetics at the Sidney Kimmel Cancer Center of Thomas Jefferson University, discusses the decisions reached about the implementation of germline testing at the 2019 Philadelphia Prostate Cancer Consensus Conference. She summarizes the conclusions the voting participants came to, including recommendations on who should receive germline testing, what should be discussed with men in terms of informed consent, which genes should be prioritized for testing, and who should be enrolled in precision medicine trials, among other topics. In a follow-up interview, E. David Crawford, MD, Professor of Urology at the University of California, San Diego, asks Dr. Giri about which laboratories and panels to use, the limitations of commercial genetic testing like 23andMe, and the role of online genetic counseling.